Literature DB >> 3263918

Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.

J V Castell1, T Geiger, V Gross, T Andus, E Walter, T Hirano, T Kishimoto, P C Heinrich.   

Abstract

The plasma half-life of recombinant human interleukin-6 (rhIL-6) was determined in rats by measuring the disappearance of the biological activity as well as of the radioactivity of 125I-rhIL-6 from the circulation. The kinetics of clearance were biphasic. It consisted of a rapid initial disappearance corresponding to a half-life of 3 min, and of a second slow one corresponding to a half-life of about 55 min. By cellulose-acetate electrophoresis it was shown that rhIL-6 binds to a plasma protein resulting in a complex migrating in the beta-gamma region; 20 min after intravenous injection, about 80% of the 125I-rhIL-6 that had disappeared from the circulation was found in the liver. 125I-rhIL-6 was exclusively localized on the surface of parenchymal cells suggesting the existence of an interleukin-6 receptor on the hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263918     DOI: 10.1111/j.1432-1033.1988.tb14384.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  60 in total

1.  Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy.

Authors:  Ana Andres-Hernando; Belda Dursun; Christopher Altmann; Nilesh Ahuja; Zhibin He; Rhea Bhargava; Charles E Edelstein; Alkesh Jani; Thomas S Hoke; Christina Klein; Sarah Faubel
Journal:  Nephrol Dial Transplant       Date:  2012-07-09       Impact factor: 5.992

2.  Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children.

Authors:  Andrew Sawczenko; Omeia Azooz; Joanna Paraszczuk; Maja Idestrom; Nick M Croft; Martin O Savage; Anne B Ballinger; Ian R Sanderson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

3.  Increase in portal blood interleukin-6 soon after the commencement of digestive surgery.

Authors:  T Maeba; H Maeta; H Usuki; H Wakabayashi; T Tsubouchi; S Okada; T Takeda; I Hamamoto; K Okano; K Ishimura
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 4.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

5.  Gut and liver handling of interleukin-6 during liver resection in man.

Authors:  Simon A W G Dello; Johanne G Bloemen; Marcel C G van de Poll; Ronald M van Dam; Jan H M B Stoot; Maartje A J van den Broek; Wim A Buurman; Marc H A Bemelmans; Steven W M Olde Damink; Cornelis H C Dejong
Journal:  HPB (Oxford)       Date:  2011-03-07       Impact factor: 3.647

6.  Change in cardiovascular risk factors with progression of kidney disease.

Authors:  Linda F Fried; Ronit Katz; Mary Cushman; Mark Sarnak; Michael G Shlipak; Lewis Kuller; Anne B Newman
Journal:  Am J Nephrol       Date:  2008-10-24       Impact factor: 3.754

7.  Hepatic fibrosis developing in morbid obesity independent of steatohepatitis: new mechanism or the Rube Goldberg machine?

Authors:  Eric R Kallwitz
Journal:  Hepatol Int       Date:  2012-03-11       Impact factor: 6.047

8.  Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants.

Authors:  P C Ng; S H Cheng; K M Chui; T F Fok; M Y Wong; W Wong; R P Wong; K L Cheung
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-11       Impact factor: 5.747

Review 9.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

10.  Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.

Authors:  Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.